Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | PLK4 | O00444 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16344213 | 0.91 | PTGS2 (0.72) | MAPTMAPK1TP53PTGS2MEN1 | |
| SCHEMBL16234787 | 0.85 | SYK (0.57) | MAPTMAPK1TP53PTGS2MEN1 | |
| SCHEMBL31086767 | 0.82 | LMNA (0.68) | MAPTMAPK1PTGS2MEN1KMT2A | |
| SCHEMBL28085087 | 0.81 | MAPT (0.63) | MAPTMAPK1TP53PTGS2KMT2A | |
| SCHEMBL23321312 | 0.80 | LMNA (0.82) | MAPTMAPK1TP53PTGS2MEN1 | |
| SCHEMBL1658390 | 0.80 | MAPT (0.82) | MAPTMAPK1PTGS2MEN1KMT2A | |
| SCHEMBL23326428 | 0.80 | PTGS2 (0.68) | MAPTMAPK1PTGS2MEN1KMT2A | |
| SCHEMBL17908123 | 0.80 | MAPT (0.61) | MAPTMAPK1TP53PTGS2TDP1 | |
| SCHEMBL16423491 | 0.80 | PLK4 (0.70) | IGF1RPLK4AURKAAURKB | |
| SCHEMBL27776226 | 0.80 | LMNA (0.81) | MAPTMAPK1TP53PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827920-B2 | Nanostructure, a biosensor including the nanostructure, and a screening method | POSTECH Research and Business Development Foundation (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827920-B2 | Nanostructure, a biosensor including the nanostructure, and a screening method | POSTECH Research and Business Development Foundation (KR) | 2023-11-28 | — | — | US | disclosed |
| US-10814010-B2 | FOXC2 inhibitor and methods of use thereof | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190290774-A1 | FOXC2 INHIBITOR AND METHODS OF USE THEREOF | POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY (KR) | 2019-09-26 | — | — | US | disclosed |
| EP-1885487-B1 | AFFINITY ADSOBENTS FOR FIBRINOGEN | PROMETIC BIOSCIENCES LTD (GB) | 2016-03-23 | — | — | EP | disclosed |
| US-9221768-B2 | Affinity adsorbents for fibrinogen | PROMETIC BIOSCIENCES INC. (CA) | 2015-12-29 | — | — | US | disclosed |
| US-20130317217-A1 | AFFINITY ADSORBENTS FOR FIBRINOGEN | PROMETIC BIOSCIENCES LTD (BI) | 2013-11-28 | — | — | US | disclosed |
| US-8551994-B2 | Affinity adsorbents for fibrinogen | PROMETIC BIOSCIENCES LTD (IM) | 2013-10-08 | — | — | US | disclosed |
| US-20090326201-A1 | Affinity Adsorbents for Fibrinogen | PROMETIC BIOTHERAPEUTICS INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1885487-A1 | AFFINITY ADSOBENTS FOR FIBRINOGEN | Prometic Biosciences Ltd (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006120429-A1 | AFFINITY ADSOBENTS FOR FIBRINOGEN | PROMETIC BIOSCIENCES LTD. (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290774-A1 | FOXC2 INHIBITOR AND METHODS OF USE THEREOF | FOXK1, FOXO1, NCOA2 | MAPT 4522/4885MAPK1 3853/4885TP53 62/4885 |
| US-20130317217-A1 | AFFINITY ADSORBENTS FOR FIBRINOGEN | FGB, F12, F13B | MAPT 4857/4885MAPK1 4698/4885TP53 3626/4885 |
| US-10814010-B2 | FOXC2 inhibitor and methods of use thereof | FOXK1, FOXO1, NCOA2 | MAPT 4522/4885MAPK1 3853/4885TP53 62/4885 |
| US-20090326201-A1 | Affinity Adsorbents for Fibrinogen | FGB, F12, F10 | MAPT 4833/4885MAPK1 4665/4885TP53 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.